Patents by Inventor Doris Coit
Doris Coit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10287324Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.Type: GrantFiled: August 2, 2018Date of Patent: May 14, 2019Assignee: NOVARTIS AGInventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Publication number: 20190023746Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain.Type: ApplicationFiled: August 2, 2018Publication date: January 24, 2019Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Patent number: 10065994Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.Type: GrantFiled: November 19, 2015Date of Patent: September 4, 2018Assignee: Novartis AGInventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Patent number: 9744228Abstract: The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids.Type: GrantFiled: April 7, 2011Date of Patent: August 29, 2017Assignee: Norvartis AGInventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Patent number: 9428739Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: GrantFiled: November 27, 2012Date of Patent: August 30, 2016Assignee: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Publication number: 20160222066Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain.Type: ApplicationFiled: November 19, 2015Publication date: August 4, 2016Inventors: Ethan Settembre, Angelica MEDINA-SELBY, Doris COIT, Philip R. DORMITZER
-
Publication number: 20130273109Abstract: The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids.Type: ApplicationFiled: April 7, 2011Publication date: October 17, 2013Applicant: NOVARTIS AGInventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Publication number: 20130171185Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.Type: ApplicationFiled: July 5, 2011Publication date: July 4, 2013Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Patent number: 8475808Abstract: Recombinant production of immunogenic West Nile Virus (WNV) proteins is described. These proteins, heterodimers comprising the proteins, fusions thereof, polynucleotides encoding the proteins, and combinations thereof, as well as antibodies produced therefrom, can be used in immunogenic compositions for preventing, treating and diagnosing WNV infection. Also described are highly sensitive ELISA and strip immunoassay methods for detecting the presence of WNV in biological samples.Type: GrantFiled: May 21, 2004Date of Patent: July 2, 2013Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: William Andrews, David Chien, Qui-Lim Choo, Stephen Coates, Doris Coit, Charles Harrington, Susan Hilt, Michael Houghton, Angelica Medina-Selby, Sergio Pichuantes, Yiu-Lian Fong
-
Patent number: 8216590Abstract: The invention provides HCV fusion polypeptides including truncated or full-length HCV NS5 polypeptides, and a portion of the HCV NS2 polypeptide, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize against HCV.Type: GrantFiled: August 27, 2007Date of Patent: July 10, 2012Assignee: Novartis AGInventors: Michael Houghton, Yin-Ling Lin, Angelica Medina-Selby, Doris Coit
-
Publication number: 20120141529Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: ApplicationFiled: January 20, 2012Publication date: June 7, 2012Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Patent number: 8142793Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: GrantFiled: March 24, 2009Date of Patent: March 27, 2012Assignee: Novartis Vaccines & Diagnostics, Inc.Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Patent number: 8124104Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: GrantFiled: March 24, 2009Date of Patent: February 28, 2012Assignee: Novartis Vaccines & Diagnostics, IncInventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Patent number: 8119145Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: GrantFiled: March 24, 2009Date of Patent: February 21, 2012Assignee: Novartis Vaccines & Diagnostics, Inc.Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Publication number: 20110104192Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: ApplicationFiled: December 10, 2010Publication date: May 5, 2011Inventors: Doris COIT, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Patent number: 7888004Abstract: Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are also disclosed.Type: GrantFiled: October 3, 2008Date of Patent: February 15, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Doris Coit, Angelica Medina-Selby, Mark Selby, Michael Houghton
-
Publication number: 20110014652Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: ApplicationFiled: March 24, 2009Publication date: January 20, 2011Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Publication number: 20110014219Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: ApplicationFiled: March 24, 2009Publication date: January 20, 2011Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Patent number: 7871625Abstract: Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.Type: GrantFiled: August 26, 2005Date of Patent: January 18, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: David Chien, Doris Coit, Carlos George-Nascimento, Sansan Lin, Angelica Medina-Selby, Laura Tandeske
-
Publication number: 20100291134Abstract: The invention provides truncated HCV NS5 polypeptides and fusion proteins comprising the truncated NS5 polypeptides, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.Type: ApplicationFiled: July 30, 2010Publication date: November 18, 2010Inventors: Michael Houghton, Angelica Medina-Selby, Doris Coit